|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 157.10 EUR | +1.29% |
|
+3.83% | +32.02% |
| 06-05 | HC Wainwright Starts Ipsen Coverage with Buy Rating | MT |
| 06-02 | Fulcrum plummets over 50% after scrapping lead sickle-cell drug on FDA concerns | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 14.71B | |||||
| 1,013B | |||||
| 574B | |||||
| 397B | |||||
| 324B | |||||
| 280B |
- Stock Market
- Stocks
- IPN Stock
- Charts Ipsen
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
